文献速递神经肿瘤

内镜经蝶垂体腺瘤手术对内分泌功能的影响:单中心研究

The impact of endoscopic transsphenoidal pituitary adenoma surgery on endocrine function: a single-centre study.
PubMed 文献 · Acta Neurochir (Wien) · 2020-10-21

结果显示61%患者无需激素替代治疗,39%术前需激素替代;术后18%出现新发垂体功能缺陷,仅6例(11%)停用激素替代。结论认为内镜术后垂体功能恢复有限且新发缺陷仍存在,需加强术前咨询。

要点

  • 内镜经蝶术后18%出现新发垂体功能缺陷,仅少数可停用激素替代。
  • 术前39%需激素替代治疗,术后多数仍需持续替代。
  • 新发尿崩症占4%,需关注术后水盐代谢。

核心结论

  • 内镜经蝶手术后垂体功能恢复能力有限,且新发缺陷仍会发生。
  • 激素替代治疗显著影响生活质量,术前咨询应据此进行。
  • 需要更大规模、更长随访的多中心协作研究评估内分泌结局。

研究设计与样本

  • 单中心回顾性分析前瞻性维护的垂体数据库。
  • 纳入2011年5月至2017年5月由同一神经外科医生行内镜经蝶手术的成人垂体腺瘤患者。
  • 纳入功能性和无功能性腺瘤。
  • 激素状态在最近一次随访时评估。

主要发现

  • 术前29例(20%)存在下丘脑-垂体-肾上腺轴功能障碍,39例(27%)存在甲状腺轴功能障碍。
  • 术前男性11例(16%)、女性7例(9%)存在性腺轴功能障碍,1例术前有尿崩症。
  • 术后26例(18%)出现新发垂体功能缺陷,6例(11%)能够停用激素替代治疗。

临床怎么用

  • 术前应告知患者内镜经蝶术后垂体功能恢复概率有限且可能新发缺陷。
  • 术后需监测下丘脑-垂体-肾上腺轴、甲状腺轴、性腺轴及尿崩症。
  • 对需激素替代治疗者应长期随访管理以维持生活质量。

局限性

  • 单中心、单术者回顾性研究,结果外推需谨慎。
  • 激素状态仅在最近一次随访评估,缺乏动态变化数据。
  • 作者指出需要更大规模、更长随访的多中心协作研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The outcome for pituitary endocrine function following endoscopic transsphenoidal surgery remains unclear. This study aims to evaluate endocrine outcomes following endoscopic surgery in order to provide a benchmark to assist in the counselling of patients perioperatively. METHODS: A prospectively held pituitary database was retrospectively analysed for all adult pituitary adenoma patients undergoing endoscopic surgery from May 2011 to May 2017. All operations were performed by a single neurosurgeon at a regional centre for pituitary surgery. Functioning and non-functioning adenomas were included. Hormonal status was assessed at most recent follow-up. RESULTS: One hundred forty-five patients (69 M, 76 F) were included in the study with a median age of 52 years. Median follow-up was 52 months. Eighty-eight patients (61%) were not taking any hormone replacement medications, whilst 57 patients (39%) required hormone replacement therapy (HRT) preoperatively. Preoperatively, 29 patients (20%) had hypothalamo-pituitary-adrenal (HPA) axis dysfunction, 39 patients (27%) had thyroid axis dysfunction, 11 males (16%) and 7 females (9%) had gonadal axis dysfunction, and one patient had preoperative diabetes insipidus. Postoperatively, 26 patients (18%) had a new deficiency in pituitary function, whilst 6 patients (11%) were able to cease HRT. Nineteen patients (13%) had new HPA axis deterioration, 12 (8%) had new thyroid axis dysfunction, 8 males (11%) and 4 females (5%) had gonadal axis deterioration, and 6 patients (4%) had new diabetes insipidus (DI). CONCLUSIONS: The ability to restore pituitary function following endoscopic surgery remains limited, whilst new deficits still occur. It is essential that patients are counselled accordingly as hormonal replacement therapy can have a significant impact on quality of life. Larger longer-term collaborative studies of endocrine outcome in endoscopic pituitary surgery are needed.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Galloway L, Ali M, Lansdown A, et al. The impact of endoscopic transsphenoidal pituitary adenoma surgery on endocrine function: a single-centre study. Acta Neurochir (Wien). 2020. PMID: 33089449. doi:10.1007/s00701-020-04609-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。